CMC

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.

Wheeler Bio

Preclinical Data

Transforming Drug Development with Frictionless Access to Real-Time Preclinical Data

Mark Mintz; Kristen M. Eisenhauer

Charles River Laboratories

Analytical Services

Expecting More for Drug Discovery and Development

Inotiv

Tissue Models

Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Ron Laethem, Ph.D.

Altis Biosystems